Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 5, 2012, Pages 1323-1332

  Gong, Jian Hua ^a   Liu, Xiu Jun ^a   Li, Yi ^a   Zhen, Yong Su ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

Bleomycin; Cetuximab; EGFR; Esophageal cancer; Pingyangmycin

Indexed keywords

BLEOMYCIN A5; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; BLEOMYCIN; DRUG DERIVATIVE; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL NUCLEUS; CELL VOLUME; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; ESOPHAGUS CANCER; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLEOMYCIN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG SYNERGISM; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862272259     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1827-9     Document Type: Article

References (33)

1. Zhen YS, Li DD, Li Q et al (1981) Studies on antitumor effect and pharmacology of pingyangmycin. Topics on cancer chemotherapy. In: Proceedings of international symposium on adriamycin and other drugs in antitumor chemotherapy, China Academic Publishers, pp 211-224
2. Zhen YS, Li DD (2009) Antitumor antibiotic pingyangmycin: research and clinical use for 40 years. Chin J Antibiot 34:577-580
3. Byrnes RW, Templin J, Sem D, Lyman S, Petering DH (1990) Intracellular DNA strand scission and growth inhibition of Ehrlich ascites tumor cells by bleomycins. Cancer Res 50:5275-5286 (Pubitemid 20302975)
4. Chen J, Stubbe J (2005) Bleomycins: towards better therapeutics. Nat Rev Cancer 5:102-112 (Pubitemid 40215859)
5. Williams ED, Merrick MV, Lavender JP (1975) The distribution and dosimetry of 111In-Bleomycin in man. Br J Radiol 48:275-278
6. Homs MY, Voest EE, Siersema PD (2009) Emerging drugs for esophageal cancer. Expert Opin Emerg Drugs 14:329-339
7. Mariette C, Piessen G, Triboulet JP (2007) Therapeutic strategies in esophageal carcinoma: role of surgery and other modalities. Lancet Oncol 8:545-553 (Pubitemid 46813024)
8. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in esophageal carcinoma: a metaanalysis. Lancet Oncol 8:226-234 (Pubitemid 46291702)
9. Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103:211-225
10. Gibault L, Metges JP, Conan-Charlet V, Lozac'h P, Robaszkiewicz M, Bessaguet C, Lagarde N, Volant A (2005) Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer 93:107-115 (Pubitemid 41076258)
11. Itakura Y, Sasano H, Shiga C, Furukawa Y, Shiga K, Mori S, Nagura H (1994) Epidermal growth factor receptor overexpression inesophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 74:795-804 (Pubitemid 24237457)
12. Yano H, Shiozaki H, Kobayashi K, Yano T, Tahara H, Tamura S, Mori T (1991) Immunohistologic detection of the epidermal growth factor receptor in human esophageal squamous cell carcinoma. Cancer 67:91-98
13. Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N, Ooi A (2006) EGFRprotein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 118:1173-1180 (Pubitemid 43185604)
14. Miyawaki M, Hijiya N, Tsukamoto Y, Nakada C, Kawahara K, Moriyama M (2008) Enhanced phosphorylation of the epidermal growth factor receptor at the site of tyrosine 992 in esophageal carcinomas. APMIS 116:1097-1106
15. Carneiro A, Isinger A, Karlsson A, Johansson J, Jönsson G, Bendahl PO, Falkenback D, Halvarsson B, Nilbert M (2008) Prognostic impact of array-based genomic profiles in esophageal squamous cell cancer. BMC Cancer 11:98-106
16. Boone J, van Hillegersberg R, Offerhaus GJ, van Diest PJ, Borel Rinkes IH, Ten Kate FJ (2009) Targets for molecular therapy in esophageal squamous cell carcinoma: an immunohistochemical analysis. Dis Esophagus 22:496-504
17. Cao SS, Zhen YS (1989) Potentiation of antimetabolite: antitumor activity in vivo by dipyridamole and amphotericin B. Cancer Chemother Pharmacol 24:181-186
18. Zhen YS, Taniki T, Weber G (1992) Azidothymidine and dipyridamole as biochemical response modifiers: synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells. Oncol Res 4:73-88
19. Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J (2004) Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 10:6487-6501 (Pubitemid 39346544)
20. Yokoyama Y, Dhanabal M, Griffioen AW, Sukhatme VP, Ramakrishnan S (2000) Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res 60:2190-2196 (Pubitemid 30225182)
21. Wei Q, Chen L, Sheng L, Nordgren H, Wester K, Carlsson J (2007) EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol 31:493-499
22. Langer R, Von Rahden BH, Nahrig J, Von Weyhern C, Reiter R, Feith M, Stein HJ, Siewert JR, Höfler H, Sarbia M (2006) Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study. J Clin Pathol 59:631-634 (Pubitemid 43886048)
23. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578 (Pubitemid 43209104)
24. Safran H, Suntharalingam M, Dipetrillo T, Ng T, Doyle LA, Krasna M, Plette A, Evans D, Wanebo H, Akerman P, Spector J, Kennedy N, Kennedy T (2008) Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys 70:391-395
25. Gold PJ, Goldman B, Iqbal S, Leichman LP, Lenz HJ, Blanke CD (2010) Cetuximab as second-line therapy in patients with metastatic esophageal cancer: a phase II Southwest Oncology Group Study. J Thorac Oncol 5:1472-1476
26. Ku GY, Shah MA, Tang LH, Miron B, Kelsen DP, Ilson DH (2008) Cetuximab (C225) plus irinotecan/cisplatin (CPT/Cis) for CPT/Cis-refractory esophageal cancer. J Clin Oncol 26(Supplement; ASCO Meeting Abstracts):15580
27. Hollstein MC, Smits AM, Galiana C, Yamasaki H, Bos JL, Mandard A, Partensky C, Montesano R (1988) Amplification of epidermal growth factor receptor gene but no evidence of ras mutations in primary human esophageal cancers. Cancer Res 48:5119-5123
28. Hollstein MC, Peri L, Mandard AM, Welsh JA, Montesano R, Metcalf RA, Bak M, Harris CC (1991) Genetic analysis of human esophageal tumors from two high incidence geographic areas: frequent p53 base substitutions and absence of ras mutations. Cancer Res 51:4102-4106
29. Lyronis ID, Baritaki S, Bizakis I, Krambovitis E, Spandidos DA (2008) K-ras mutation, HPV infection and smoking or alcohol abuse positively correlate with esophageal squamous carcinoma. Pathol Oncol Res 14:267-273
30. Nakayama Y, Igarashi A, Kikuchi I, Obata Y, Fukumoto Y, Yamaguchi N (2009) Bleomycin-induced over-replication involves sustained inhibition of mitotic entry through the ATM/ ATR pathway. Exp Cell Res 315:2515-2528
31. Zhou BB, Elledge SJ (2000) The DNA damage response: putting checkpoints in perspective. Nature 408:433-439
32. Benhar M, Engelberg D, Levitzki A (2002) ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep 3:420-425 (Pubitemid 34567428)
33. Oliveras-Ferraros C, Vazquez-Martin A, López-Bonet E, Martín-Castillo B, Del Barco S, Brunet J, Menendez JA (2008) Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triplenegative/ basal-like breast cancer. Int J Oncol 33:1165-1176